APTINYX, INC.
EVANSTON, IL · Founded 2015 · CIK 0001674365 · Biotech · Defunct
NMDAR partial agonist small-molecule compounds (JY-505,317 and related series) that modulate glutamatergic signaling to treat neuropathic pain
- Grants
- $2.8M
- 4 awards
- Sector median: 1
- Raised
- $95M
- 2 Form D · Dec 2017
- 106 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 26 granted · 14 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2015201620172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Nmda Receptor Modulators As Nootropic Therapies In Aging Brain | $311,866 | |
| Private capital raised | Form D · SEC | $24,999,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Mitigating Taxol-Induced Neuropathy through Modulation of the NMDA Receptor | $197,633 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Pharmacological Treatment for Neuropathic Pain | $1,249,376 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel Pharmacological Treatment for Neuropathic Pain | $1,090,948 | |
| Private capital raised | Form D · SEC | $70,000,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1483 | Modulate Bio Inc. | — | $200K |
| 1484 | Aperta Biosciences, LLC | — | $175K |
| 1485 | Treovir, Inc. | — | $133K |
| 1486 | APTINYX, INC. | — | $95M |
| 1487 | Selva Nexus, Inc. | — | $50K |
| 1488 | NOVOBIOTIC PHARMACEUTICALS, LLC | — | — |
| 1489 | Cellevate Inc. | — | $25K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Patrick EnrightDirector
- Wilbur Gantz IIIDirector
- Terry GouldDirector
- Ashish KhannaExecutive Officer
- Andrew KiddExecutive Officer
- Adam KoppelDirector
- Torsten MadsenExecutive Officer
- Joseph MoskalExecutive Officer
- Liam RatcliffeDirector
- Norbert RiedelDirector · Executive Officer
- James TopperDirector
Patents
- Spiro-lactam Compounds And Methods Of Treating Viral Infections Using The Sameapplication
- Spiro-lactam Nmda Receptor Modulators And Uses Thereofapplication
- Spiro-lactam Nmda Receptor Modulators And Uses Thereofgranted
- Spiro-lactam Nmda Receptor Modulators And Uses Thereofgranted
- Spiro-lactam Nmda Receptor Modulators And Uses Thereofgranted
- Spiro-lactam Nmda Modulators And Methods Of Using Samegranted
- Spiro-lactam Nmda Receptor Modulators And Uses Thereofgranted
- Spiro-lactam Nmda Modulators And Methods Of Using Samegranted
- Spiro-lactam Nmda Receptor Modulators And Uses Thereofgranted
- Spiro-lactam And Bis-spiro-lactam Nmda Receptor Modulators And Uses Thereofapplication
- Methods Of Treating Cognitive Impairment Associated With Neurodegenerative Diseaseapplication
- Methods Of Treating Fibromyalgiaapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.